Denali receives $200M from Royalty Pharma following FDA accelerated approval of tividenofusp alfa

Filed March 31, 2026 · Period ending March 27, 2026 · ~1 min read

Key Changes

• high

  FDA granted accelerated approval to tividenofusp alfa on March 24, 2026, allowing Denali to commercialize the drug and triggering a previously disclosed royalty funding agreement.

  Item 2.03 verify on EDGAR →
• high

  Denali received $200 million in gross proceeds on March 27, 2026 from closing the synthetic royalty agreement with Royalty Pharma, strengthening the company's cash position.

  Item 2.03 verify on EDGAR →
• medium

  The royalty agreement was previously disclosed in a December 4, 2025 Form 8-K, with funding contingent on regulatory approval milestones.

  Item 2.03 verify on EDGAR →